{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=21", "query": { "condition": "Urogenital Neoplasms", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 8979, "total_pages": 898, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urogenital+Neoplasms&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:26:23.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive", "Metastatic Malignant Neoplasm", "Recurrent Anal Canal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Penile Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Refractory Malignant Neoplasm", "Stage IV Anal Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-11-14", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439085" }, { "nct_id": "NCT03945162", "title": "Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG" ], "interventions": [ { "name": "Ruvidar® (TLD-1433) bladder infusion and PDT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Theralase® Technologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2019-08-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 10, "location_summary": "Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Greenwood", "state": "Indiana" }, { "city": "Syracuse", "state": "New York" }, { "city": "Gahanna", "state": "Ohio" }, { "city": "Bala-Cynwyd", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945162" }, { "nct_id": "NCT06005818", "title": "Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-01-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005818" }, { "nct_id": "NCT03551782", "title": "A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostatic Neoplasms" ], "interventions": [ { "name": "Cetrelimab 480 mg", "type": "DRUG" }, { "name": "Apalutamide 240 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 33, "start_date": "2018-06-28", "completion_date": "2021-11-11", "has_results": false, "last_update_posted_date": "2022-02-25", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 11, "location_summary": "San Francisco, California • Shreveport, Louisiana • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Bay Saint Louis", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03551782" }, { "nct_id": "NCT07874880", "title": "MTX-531-001 Phase 1 Study in Advanced Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors (Phase 1)", "HNSCC", "Endometrial Cancer", "Her2-negative Metastatic Breast Cancer", "Pan-RAS and BRAF Wild-type Advanced", "Metastatic Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "MTX-531", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEKanistic Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2026-10-20", "completion_date": "2029-09-29", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07874880" }, { "nct_id": "NCT00722553", "title": "Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Bladder Cancer", "Bladder Neoplasm" ], "interventions": [ { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-07", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 4, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722553" }, { "nct_id": "NCT04106245", "title": "Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Carcinoma" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 145, "start_date": "2019-12-04", "completion_date": "2023-07-27", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106245" }, { "nct_id": "NCT00869206", "title": "Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Adenocarcinoma", "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "Metastatic Malignant Neoplasm to the Bone", "Pain", "Musculoskeletal Complication", "Urinary Complications" ], "interventions": [ { "name": "zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1822, "start_date": "2009-03", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 503, "location_summary": "Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fairfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869206" }, { "nct_id": "NCT02209584", "title": "Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Myriad Genetic Laboratories, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 274, "start_date": "2014-05", "completion_date": "2015-12-08", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02209584" }, { "nct_id": "NCT07247058", "title": "Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Mild Autonomous Cortisol Secretion (MACS)" ], "interventions": [ { "name": "Osilodrostat (Isturisa)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-02-02", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-15T13:26:23.521Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07247058" } ] }